BCAL Diagnostics (ASX:BDX) EBIT per Share : A$-0.03 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics EBIT per Share?

BCAL Diagnostics's EBIT per Share for the six months ended in Dec. 2023 was A$-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for BCAL Diagnostics's EBIT per Share or its related term are showing as below:

ASX:BDX's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: -1.7
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

BCAL Diagnostics's EBIT for the six months ended in Dec. 2023 was A$-2.35 Mil.

BCAL Diagnostics EBIT per Share Historical Data

The historical data trend for BCAL Diagnostics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics EBIT per Share Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

EBIT per Share

-0.02

-0.04

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial			-0.01	-0.01	-0.02	-0.02	-0.01

BCAL Diagnostics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

BCAL Diagnostics's EBIT per Share for the fiscal year that ended in Jun. 2023 is calculated as

	EBIT per Share		(A: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-7.898	/	210.903
=	-0.04

BCAL Diagnostics's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.353	/	231.397
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.03

BCAL Diagnostics (ASX:BDX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

BCAL Diagnostics EBIT per Share Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.